Reneo Pharma Q2 net loss $5.4M; merger with OnKure on track for H2 2024

OnKure Therapeutics, Inc.

2024-Q2 EPS reported -$0.41

Net loss of $5.4M ($0.16 per share) vs $19.5M ($0.65) in Q2 2023; cash $76.7M at June 30.
R&D expenses fell to $0.6M from $14.4M due to suspension of mavodelpar development and workforce cuts.
Merger with OnKure (all-stock) plus $65M PIPE expected to close H2 2024; combined cash ~$120M.
General and administrative expenses $5.8M vs $6.6M, with $2.4M increase in legal/advisory fees for merger.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.